Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperpigmentation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Hyperpigmentation. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-003608-41 Sponsor Protocol Number: RD.06.SPR.204245 Start Date*: 2022-01-12
    Sponsor Name:Galderma S.A.
    Full Title: Evaluation of acne-induced hyperpigmentation during treatment of acne vulgaris subjects with trifarotene 50 µg/g cream versus vehicle cream over 24 weeks.
    Medical condition: Moderate acne vulgaris with acne-induced post-inflammatory hyperpigmentation (PIH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-002756-11 Sponsor Protocol Number: 43739 Start Date*: 2014-08-27
    Sponsor Name:Department of Dermatology D92, Bispebjerg Hospital
    Full Title: Photodynamic therapy with varying application times for treatment of actinic keratosis
    Medical condition: Actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000304-26 Sponsor Protocol Number: GS-US-162-0112 Start Date*: 2015-01-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa with Continued Access to Emtricitabine.
    Medical condition: Human Immunodeficiency Virus, Type 1 (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-000115-10 Sponsor Protocol Number: SPON CU 086 Start Date*: 2005-10-14
    Sponsor Name:Cardiff University
    Full Title: A randomised, double blind, placebo-controlled, cross-over study of the effects of dehydroepiandrosterone replacement on vascular function in patients with primary and secondary adrenal insufficiency.
    Medical condition: Primary and secondary adrenal failure
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003234-82 Sponsor Protocol Number: NTMT-03-A Start Date*: 2018-06-13
    Sponsor Name:Neurotech Pharmaceuticals
    Full Title: A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia type 2
    Medical condition: Macular Telangiectasia type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000749-15 Sponsor Protocol Number: NL73142.068.20 Start Date*: 2020-08-26
    Sponsor Name:Academisch ziekenhuis Maastricht
    Full Title: Resolution Enhancement by a Supplemental Open-Label Venoactive drug for Eight weeks in Deep Vein Thrombosis
    Medical condition: Post-thrombotic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001598-93 Sponsor Protocol Number: C-02-60 Start Date*: 2005-07-05
    Sponsor Name:Alcon Research Limited
    Full Title: An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) versus Sham Administration in Patients (Enrolled in Study ...
    Medical condition: non-exudative age related macular degeneration (dry AMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-005438-39 Sponsor Protocol Number: 40736 Start Date*: 2014-04-01
    Sponsor Name:Department of Dermatology D92, Bispebjerg Hospital
    Full Title: Pulse photodynamic therapy with methyl aminolevulinate activated by a halogen lamp
    Medical condition: Actinic keratoses
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002583-80 Sponsor Protocol Number: 38814 Start Date*: 2013-09-06
    Sponsor Name:Department of Dermatology, Bispebjerg University Hospital
    Full Title: Treatment of Actinic Keratoses with Ingenol Mebutate and topical glucocorticosteroid - a safety study
    Medical condition: Actinic Keratoses
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003771-20 Sponsor Protocol Number: BI 1138.10 Start Date*: 2006-02-09
    Sponsor Name:Boehringer Ingelheim GmbH
    Full Title: A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suf...
    Medical condition: chronic venous insufficiency
    Disease: Version SOC Term Classification Code Term Level
    8.1 10047220 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-001659-11 Sponsor Protocol Number: BELKYRA-HYPOGASTRIUM Start Date*: 2018-10-19
    Sponsor Name:COSMETIC SURGERY BCN SLP
    Full Title: A pilot study to evaluate the safety and efficacy of the application of Belkyra™ in the fat located in the hypogastric zone.
    Medical condition: Subjects with fat located in the treatment area (hypogastrium)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000487-92 Sponsor Protocol Number: SPJK/06/01 Start Date*: 2006-11-21
    Sponsor Name:Royal College of Surgeon's Ireland
    Full Title: A Phase II, Randomised, Double Blind, Placebo Controlled Study examining the suitability of Phenytoin Sodium Topical Gel in the treatement of Venous Ulcers
    Medical condition: Venous ulcers in the lower leg.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001448-13 Sponsor Protocol Number: RD.03.SPR.105041 Start Date*: 2015-07-09
    Sponsor Name:Galderma R&D
    Full Title: Benzaknen® 5% Gel in combination with Dermotivin® Soft Liquid cleanser and non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the treatment of mild-to-moderate acne vulgaris
    Medical condition: Acne vulgaris (AV)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004804-23 Sponsor Protocol Number: KCT13/2017–FLEBAVEN/SI Start Date*: 2018-06-15
    Sponsor Name:Krka, d.d., Novo mesto
    Full Title: The efficacy and safety of a single dose Flebavena® (Diosmin) of 1000 mg per day in patients with chronic venous disease (LIGHTEN-UP)
    Medical condition: Patients diagnosed with primary chronic vein disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10066682 Chronic venous insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2017-000746-22 Sponsor Protocol Number: 874-2017 Start Date*: 2017-06-22
    Sponsor Name:Department of Dermatology, Zealand University Hospital, Roskilde
    Full Title: Vascular changes in basal cell carcinoma undergoing either electrochemotherapy or photodynamic therapy - assessed with optical coherence tomography
    Medical condition: Basal cell carcinoma in adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003260-12 Sponsor Protocol Number: NTMT-03-B Start Date*: 2018-10-02
    Sponsor Name:Neurotech Pharmaceuticals Inc.
    Full Title: A Phase 3 Multicenter Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia type 2
    Medical condition: Macular Telangiectasia type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002823-46 Sponsor Protocol Number: LT4030-201 Start Date*: 2018-09-11
    Sponsor Name:Laboratoires THÉA; Research and Development Department
    Full Title: Efficacy and safety assessment of T4030 eye drops (unpreserved fixed combination of bimatoprost 0.01% and timolol 0.1% or 0.5%) versus Ganfort® UD (Unit Dose) in ocular hypertensive or glaucomatous...
    Medical condition: Glaucoma, ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001001-40 Sponsor Protocol Number: DT-DP-UC-CR-01 Start Date*: 2014-06-13
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A multicentre, double-blind, randomised, controlled phase II/III study to evaluate the efficacy and safety of the new wound healing solution Diperoxochloric acid (DPOCl, DermaPro®) in patients with...
    Medical condition: Venous leg ulcer (ulcus cruris)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003733-23 Sponsor Protocol Number: CB-03-01/34 Start Date*: 2017-05-09
    Sponsor Name:Cassiopea S.p.A.
    Full Title: A PHASE 2, MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB 03 01 (CORTEXOLONE 17α-PROPIONATE) SOLUTION FOR THE...
    Medical condition: AGA (androgenic alopecia) is scalp hair loss that occurs due to an underlying susceptibility of hair follicles to androgenic miniaturization. In the hair follicle, testosterone is converted by 5α-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10068558 Androgenic alopecia LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002843-14 Sponsor Protocol Number: 0407 Start Date*: 2017-09-26
    Sponsor Name:Bispebjerg Hospital
    Full Title: Investigations of local skin reactions and safety after combined treatment of basal cell carcinoma using ablative fractional laser and ingenol mebutate - an exloratory, prospective, open-label phas...
    Medical condition: Safety and local skin reactions in patients with basal cell carcinoma after combined treatment of blative fractional laser and ingenol mebutate.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA